Growth Hormone Release & Fat Reduction. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to produce and release gro...
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to produce and release growth hormone. It is the only GHRH analog with FDA approval — specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy (marketed as Egrifta). It has gained significant popularity for body composition optimization.
Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating synthesis and pulsatile release of endogenous GH. Unlike exogenous GH, tesamorelin preserves natural feedback mechanisms, resulting in more physiological GH release. This leads to increased IGF-1, enhanced lipolysis (particularly visceral fat), and improved body composition without supraphysiological GH levels.
Important: The evidence base for Tesamorelin varies by application. Many findings are from preclinical (animal or in vitro) studies. Large-scale human clinical trials may not be completed. Always evaluate the quality of evidence before drawing conclusions.
Common side effects include injection site reactions, joint pain, peripheral edema, and paresthesia. Less common: elevated blood glucose and carpal tunnel-like symptoms. Long-term GH elevation carries theoretical oncological risks, though clinical data has not confirmed this.
Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Off-label use requires a prescription. Available from compounding pharmacies and as a research chemical. Prohibited by WADA.
These verified suppliers carry Tesamorelin with third-party COAs and US-based shipping.